Enzalutamide in Men With High-Risk Biochemically Recurrent Prostate Cancer: Rationale and Treatment Considerations From EMBARK

Neal D Shore¹, Ugo De Giorgi², Stephen J Freedland^{3

4}

Affiliations

¹ Carolina Urologic Research Center, Myrtle Beach, South Carolina.
² Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola, Italy.
³ Department of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
⁴ The Durham VA Medical Center, Durham, North Carolina.

Editorial

Neal D Shore et al. J Urol. 2025 Jan.

. 2025 Jan;213(1):110-113.

doi: 10.1097/JU.0000000000004228. Epub 2024 Sep 3.

Neal D Shore¹, Ugo De Giorgi², Stephen J Freedland^{3

4}

¹ Carolina Urologic Research Center, Myrtle Beach, South Carolina.
² Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola, Italy.
³ Department of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
⁴ The Durham VA Medical Center, Durham, North Carolina.

No abstract available

Keywords: EMBARK; enzalutamide; high-risk biochemical recurrence; prostate cancer.

Comment in

Editorial Comment.
Kronstedt S, Singer EA. Kronstedt S, et al. J Urol. 2025 Jan;213(1):113. doi: 10.1097/JU.0000000000004243. Epub 2024 Sep 27. J Urol. 2025. PMID: 39330871 No abstract available.